Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

Poster presentations: Track A

02008 WATER DISPERSIBLE MICROBICIDAL CELLULOSE ACETATE PHTHALATE FILM

02114_1 EFFECTS OF CANDIDATE MICROBICIDES PRO2000 AND SAMMA ON DC-SIGN MEDIATED INFECTION OF CD4+ T-CELLS

02183 CELLULOSE ACETATE PHTHALATE INHIBITS INFECTION BY CELL-FREE & CELL-ASSOCIATED PRIMARY HIV-1 STRAINS

02202 STRUCTURAL STUDIES OF APTAMERS THAT NEUTRALIZE R5 SRTAIN OF HIV-1

02225 ANTI-HIV AND OTHER STD PATHOGEN ACTIVITIES OF A COMBINATIONAL MICROBICIDE CANDIDATE, PL40

02229_1 SEX HORMONE RECEPTOR, ADHESION MOLECULE AND ANTIBODY PRODUCTION IN ANTIBOBY-SECRETING CELLS

02229_2 SECRETORY COMPONENT IS DISTRIBUTED IN MOUSE PROSTATE EPITHELIA, AND UP-REGULATED BY TESTOSTERONE

02230 IN VITRO SAFETY EVALUATION OF A COMBINATIONAL MICROBICIDE CANDIDATE, PL40,

02243 EVALUATION OF ANTIMICROBIAL AND CONTRACEPTIVE ACTIVITIES OF NISIN: IN VITRO AND IN VIVO STUDIES

02321 A POTENTIAL ANTI-HERPES SIMPLEX VIRUS AGENT FROM A KENYAN MEDICINAL PLANT

02337 CYTOKINE EXPRESSION IN CERVICOVAGINAL COMPARTMENT OF INDIAN WOMEN

02343_1 PRECLINICAL EVALUATIONS OF DENDRIMER FORMULATIONS IN THE NONHUMAN PRIMATE MODEL

02343_2 CELLULOSE SULFATE SAFETY AND EFFICACY STUDIES IN THE MACAQUE MODEL

02343_3 PRECLINICAL SAFETY EVALUATION OF ACIDFORM IN THE MACAQUE MODEL

02346_1 THE EVALUATION OF THE LOCAL TOLERANCE OF VAGINAL FORMULATIONS USING THE SLUG MUCOSAL IRRITATION TEST

02346_2 EVALUATION OF THE LOCAL TOLERANCE OF VAGINAL FORMULATIONS CONTAINING TMC 120 USING RABBITS AND SLUGS

02349 IS GLYCERIN A NATURAL MICROBICIDE AGAINST HIV IN THE UPPER GASTROINTESTINAL TRACT?

02352 THETA-DEFENSINS PROTECT CELLS FROM INFECTION BY HERPES SIMPLEX VIRUS 

02387 EUROPEAN MICROBICIDES PROJECT

02395 CHARACTERIZATION OF AN EX VIVO/IN VITRO INTESTINAL EXPLANT MODEL FOR RECTAL MICROBICIDE DEVELOPMENT.

02421 MICROBICIDAL DETERGENTS INCREASE HSV SUSCEPTIBILITY IN MICE W/O CAUSING VISIBLE EPITHELIAL DEFECTS

02438 DEVELOPMENT OF AN IN VITRO DUAL-CHAMBER MODEL FOR EVALUATION OF CANDIDATE MICROBICIDES

02439 COMPARISON OF DRUG ABSORPTION FOLLOWING INTRAVAGINAL ADMINISTRATION TO RATS AND RABBITS

02442 PMPA- NNRTI COMBINATION STUDIES DEMONSTRATE POTENT SYNERGISM AGAINST HIV-1 INFECTION IN VITRO

02444 MANNOSE-SPECIFIC PLANT LECTINS AS POTENTIAL HIV MICROBICIDES

02445 CARRAGUARD PREVENTS MACROPHAGE TRAFFICKING FROM VAGINA - IMPLICATIONS FOR MICROBICIDE DEVELOPMENT

02446 PC-815, A NOVEL COMBINATION MICROBICIDE

02451 MIV-150, A POTENT HIV-1 INHIBITOR SUITABLE FOR USE IN MICROBICIDES

02460 UC781 PROTECTS EX VIVO LYMPHOID TISSUE FROM HIV-1 INFECTION.

02466 OPTIMIZING EXPRESSION OF PROTEIN MICROBICIDES IN LACTOBACILLI: BENEFITS OF GENOMIC SEQUENCING

02467 A PATHOGENIC CCR5-UTILIZING SHIV162PT CAN IMPROVE MACAQUE MODEL FOR TOPICAL MICROBICIDE EVALUATION

02479 BIOCHEMICAL EVALUATION OF FUNGISTATIC PROPERTIES OF AQUEOUS GARLIC EXTRACT AGAINST HIV1/AIDS CANDIDA ISOLATES FROM NIGERIA

02499 DIETARY FLAVONOIDS REDUCE THE PRODUCTION OF HERPES SIMPLEX VIRUS (HSV)

02503 K5 POLYSACCHARIDE DERIVATIVE: POTENTIAL CANDIDATE MICROBICIDE FOR PREVENTION OF HIV-1 INFECTION

02507 SAMMA BLOCKS HIV-1 AND HSV-2 INFECTION IN CELLULAR AND HUMAN CERVICAL TISSUE MODELS

02509 PREVENTION OF HIV-1 INFECTION BY PLATINUM TRIAZINES

02515 HIGH-EFFICIENT MEMBRANE-ACTING NORBORNENE- AND NORBORNANE-CONTAINING ANTI-HIV MICROBICIDES

02562 MUCOSAL DELIVERY OF MICROBICIDES BY COMMENSAL BACTERIA: EXPRESSION OF CYANOVIRIN-N IN LACTOBACILLUS

02591 TMC120 BLOCKS HIV-1 INFECTION IN CELLULAR AND HUMAN CERVICAL TISSUE MODELS

02594 NEUTRALISING CAPACITY OF TMC120 (DAPIVIRINE) ON A RANGE OF CIRCULATING HIV-1 PRIMARY ISOLATES

02595 CONTRACEPTIVE ACTION OF CELLULOSE ACETATE PHTHALATE (CAP)

02598 HUMAN CERVICAL AND COLORECTAL EXPLANTS FOR TOXICITY AND EFFICACY TESTING OF TOPICAL MICROBICIDES

02600 AN IN VITRO COMPARISON OF TOPICAL MICROBICIDES FOR THE PREVENTION OF HIV TRANSMISSION

02605 SULFATED POLYMERS TARGET HSV GLYCOPROTEIN B, PREVENT VIRAL BINDING, ENTRY, AND CELL-TO-CELL SPREAD AND MAY IMPACT MUCOSAL IMMUNITY

02610_1 WHI-07 PREVENTS VAGINAL AND RECTAL TRANSMISSION OF FELINE IMMUNODEFICIENCY VIRUS INFECTION IN CATS

02610_2 STAMPIDINE IS A POTENTIAL NONCONTRACEPTIVE BROAD-SPECTRUM ANTI-HIV MICROBICIDE

02611_1 THE DEVELOPMENT OF A CYNOMOLOGOUS MACAQUE MODEL TO EVALUATE CANDIDATE VAGINAL MICROBICIDES

02611_2 PRECLINICAL EVALUATION OF CANDIDATE VAGINAL MICROBICIDE -2 RANTES

02612 PRODUCTION OF A RECOMBINANT HUMAN ANTI-SPERM ANTIBODY, RASA: IMPLICATIONS AS A SPERMICIDAL AGENT

02616 INTRAVAGINAL PSC-RANTES PROTECTS AGAINST VAGINAL TRANSMISSION OF SHIV-162P TO MACAQUE MONKEYS

02619 CICLOPIROXOLAMINE: A MARKETED VAGINAL PRODUCT WITH POTENTIAL AS A MICROBICIDE

02620 COMPARISON OF THE IN VITRO ACTIVITY OF MARKETED INDIAN PRODUCTS AND NONOXYNOL-9 AGAINST VAGINAL LACTOBACCILLUS

02625_1 STUDY OF GANODERMA LUCIDUM POLYSACCHARIDE ON EFFECTS OF CELLULAR IMMUNE FUNCTION IN MICE

02626 PREFORMULATION EVALUATION OF UC-781, A POTENTIAL ANTI-HIV TOPICAL MICROBICIDE CANDIDATE

02627_1 SAMMA, A NOVEL CONTRACEPTIVE MICROBICIDE, INDUCES cGMP-DEPENDENT INDUCTION OF ACROSOMAL LOSS

02627_2 T-TYPE CA 2+ CHANNELS MEDIATE SAMMA-INDUCED HUMAN ACROSOMAL LOSS

02629_1 DEVELOPMENT OF ACID-BUFFERING FILMS AS NOVEL MICROBICIDE: COMPARATIVE EVALUATION WITH ACIDFORM GEL

02629_2 DEVELOPMENT OF RAPIDLY DISINTEGRATING BIOADHESIVE VAGINAL TABLETS OF CELLULOSE SULFATE (CS)

02639_1 PRECLINICAL EVALUATION OF LEAD CANDIDATE POLYANIONIC MICROBICIDES

02639_2 THE EVALUATION OF MICROBICIDES TO PREVENT HIV-1 INFECTION OF HUMAN COLO-RECTAL TISSUE EXPLANTS

02639_3 UC-781 BLOCKS LOCALISED INFECTION AND CELL DISSEMINATION PATHWAYS WITHIN HUMAN CERVICAL TISSUE

02639_4 Concordance between different in vitro culture models designed to predict vaginal irritation and/or toxicity

02643 DESIGN AND PRECLINICAL DEVELOPMENT OF DENDRIMER BASED TOPICAL MICROBICIDES FOR HIV & STI PREVENTION

02646_1 EFFICACY OF PRO 2000/5 GEL IN A HU-SCID MOUSE MODEL FOR VAGINAL TRANSMISSION OF CELL-ASSOCIATED HIV.

02646_2 HU-SCID MOUSE MODEL FOR RECTAL TRANSMISSION OF HIV: TESTING PRO 2000/5 GEL. 

02662 POTENTIAL REMEDY’S FOR DELIVERY OF HIGH-EFFECTIVE MEMBRANE-ACTING ANTI-HIV MICROBICIDES

02656 DESIGN OF ANTI-HIV MICROBICIDES WITH INCLUSION OF PHARMACOPHORE MODIFIERS AND PSEUDO-LIGANDS

02664 DEVELOPMENT OF MICROBICIDE VEHICLES: SELECTION LINKED TO PROPERTIES GOVERNING VAGINAL DEPLOYMENT

02665 IN VITRO RELEASE OF DEXTRAN SULFATE FROM SILICONE INTRAVAGINAL RINGS

02666 PSC-RANTES: DEVELOPMENT OF A POTENT HIV ENTRY INHIBITOR FOR USE AS A VAGINAL MICROBICIDE

02689 EFFECTS OF SQUEEZING FLOWS ON DISTRIBUTION/RETENTION OF MICROBICIDE FORMULATIONS: EXPERIMENTAL SIMULATIONS & MATHEMATICAL MODELS

02690 CONTEMPORAY MATERIAL CONCEPTS FOR THE NEXT GENERATION MICROBICIDE VEHICLES

02698 MC 1220 AS KNOCKING OUT NNRTI TO PREVENT SEXUAL TRANSMISSION OF HIV

02700 VAGINAL COATING BY MICROBICIDE FORMULATIONS: DIRECT MEASUREMENT IN WOMEN AND BIOPHYSICAL PREDICTION

03206 THE PROGRAM OF THE MICROBICIDE DEVELOPMENT IN RUSSIA

03265 A NOVEL EX VIVO MODEL OF VAGINAL HIV-1 TRANSMISSION REVEALS PARALLEL RATHER THAN SEQUENTIAL TARGETING OF INTRAEPITHELIAL LANGERHANS AND T CELLS